Results 21 to 30 of about 345,692 (191)

Anti-TNF Therapy

open access: yesMicrobiology Spectrum, 2016
ABSTRACTTumor necrosis factor (TNF) is one of the most important cytokines produced by macrophages. TNF is a very important component of host defense, released very rapidly after all types of injuries and stimuli. The kinetics of TNF release are short, and so it is perhaps not surprising that prolonged TNF production is associated with pathology.
Udalova   +6 more
openaire   +3 more sources

Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry

open access: yesGastroenterology, 2020
Background and Aims The impact of Coronavirus disease 2019 (COVID-19) on patients with inflammatory bowel disease (IBD) is unknown.
E. Brenner   +14 more
semanticscholar   +1 more source

The Role of TNF-α and Anti-TNF-α Agents during Preconception, Pregnancy, and Breastfeeding

open access: yesInternational Journal of Molecular Sciences, 2021
Tumor necrosis factor-alpha (TNF-α) is a multifunctional Th1 cytokine and one of the most important inflammatory cytokines. In pregnancy, TNF-α influences hormone synthesis, placental architecture, and embryonic development.
K. Romanowska-Próchnicka   +5 more
semanticscholar   +1 more source

Tuberculosis after anti-TNF therapy [PDF]

open access: yesClinical Rheumatology, 2009
Dear Editor We read with interest the recent article by Elbek et al. [1] assessing the risk of tuberculosis in patients treated with anti-TNF therapy. The study reported that tuberculin test positivity in the area of their study was quite frequent (77.9%) and that males more frequently had positive tests.
Pamuk, Omer Nuri, Donmez, Salim
openaire   +2 more sources

The Balance of TNF Mediated Pathways Regulates Inflammatory Cell Death Signaling in Healthy and Diseased Tissues

open access: yesFrontiers in Cell and Developmental Biology, 2020
Tumor necrosis factor alpha (TNF; TNFα) is a critical regulator of immune responses in healthy organisms and in disease. TNF is involved in the development and proper functioning of the immune system by mediating cell survival and cell death inducing ...
J. Webster, D. Vučić
semanticscholar   +1 more source

Selected problems of biologic therapy in rheumatoid arthritis patients – inefficacy of several biologic therapies. Case reports

open access: yes, 2013
Wczesne, intensywne leczenie reumatoidalnego zapalenia stawów (RZS) daje większe szanse na osiągnięcie remisji i poprawę rokowania [1–3]. Podstawą terapii RZS są syntetyczne leki modyfikujące przebieg choroby (LMPCh), z metotreksatem (MTX) jako lekiem ...
R. Jeleniewicz   +3 more
semanticscholar   +1 more source

Limfocyty T regulatorowe z ekspresją L-selektyny u dzieci i młodzieży z przewlekłą cukrzycą typu 1 [PDF]

open access: yesPediatric Endocrinology, Diabetes and Metabolism, 2010
Wprowadzenie: Zaburzenia ilościowe i/lub jakościowe w populacji limfocytów T regulatorowych mogą odgrywać rolę w rozwoju chorób autoimmunologicznych, w tym cukrzycy typu 1. CD62L jest receptorem zasiedlania limfocytów do węzłów chłonnych. Na mysim modelu
Monika Ryba   +4 more
doaj  

Adipose Tissue‐Derived Biomarkers of Intestinal Barrier Functions for the Characterization of Diarrhoea‐Predominant IBS

open access: yesDisease Markers, Volume 2018, Issue 1, 2018., 2018
Background. Alterations of the small‐intestinal permeability (s‐IP) might play an essential role in a subgroup of diarrhoea‐predominant IBS (D‐IBS) patients. Goals. (a) To analyse in D‐IBS patients the symptom profile in relation to the altered (+) or not (−) s‐IP using the Gastrointestinal Symptom Rating Scale (GSRS).
Francesco Russo   +7 more
wiley   +1 more source

Anti‐TNF agents for rheumatoid arthritis [PDF]

open access: yesBritish Journal of Clinical Pharmacology, 2001
Rheumatoid arthritis (RA) is a chronic inflammatory, autoimmune disease with a prevalence of approximately 1% and an annual incidence of 0.04%. Up to 50% of patients with RA are unable to work 10 years after diagnosis. The disease is associated with significant morbidity and mortality with associated medical costs to the UK of between £240 m and £600 m
Thomas, SHL   +3 more
openaire   +4 more sources

Mucosal Healing with Anti-TNF Antibodies [PDF]

open access: yesDigestion, 2012
Nowadays, mucosal healing is regarded as a major end point in clinical trials and is increasingly used in clinical practice for the management of patients with inflammatory bowel disease. The definition of mucosal healing varies across studies and validated endoscopic scoring indices are still lacking.
Chevaux, Jean-Baptiste   +5 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy